Protocols
Adjuvant Treatment of Stage III and IV, BRAF mutated, fully resected Melanoma Using daBRAFenib and Trametinib
Adjuvant Treatment of Resected Stage III – IV NED Melanoma Using Nivolumab
Adjuvant Treatment of Resected Stage III - IV NED Melanoma Using 4-Weekly Nivolumab
Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using Pembrolizumab
Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using 6-Weekly Pembrolizumab
Neoadjuvant Treatment of Stage III Melanoma using Ipilimumab and Nivolumab
Neoadjuvant-Adjuvant Treatment of Stage IIIB to IV Melanoma Using Pembrolizumab
Treatment of Unresectable or Metastatic Melanoma Using Alternative Dosing Regimen of Ipilimumab and Nivolumab
SMAVFIPI
First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab
SMAVIPI
Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab
SMAVIPNI
Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab and Nivolumab
SMAVNIV
Treatment of Unresectable or Metastatic Melanoma Using Nivolumab
SMAVNIV4
Treatment of Unresectable or Metastatic Melanoma Using 4-Weekly Nivolumab
USMAVNIVRE
Treatment of Unresectable or Metastatic Melanoma using Nivolumab-relatlimab
SMAVPEM
Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab
SMAVPEM6
Treatment of Unresectable or Metastatic Melanoma Using 6-Weekly Pembrolizumab
USMAVTEB
Treatment of Metastatic Uveal Melanoma using Tebentafusp
Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Dabrafenib
Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using daBRAFenib and Trametinib
SMAVEB
Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using Encorafenib and Binimetinib
Treatment of Advanced C-Kit Positive Melanoma Using iMAtinib
Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Trametinib
Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using vemURAFenib and cobimetinib
Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Vemurafenib
Palliative Therapy for Malignant Melanoma with Brain Metastases Using Temozolomide
Therapy for Metastatic Malignant Melanoma Using High Dose Single Agent Dacarbazine (DTIC)
Treatment of In-Transit Melanoma using Intralesional Aldesleukin (IL-2)
Topical Immunotherapy for In-Transit Melanoma Metastases, Cutaneous Lymphoma, Basal Cell Carcinoma Using Imiquimod
Topical Therapy for Skin Cancer with PDT (Photodynamic Therapy)
Treatment of Metastatic or Locally Advanced Basal Cell Carcinoma Using Vismodegib
Second-Line Treatment of Recurrent or Metastatic Merkel Cell Carcinoma Using Avelumab
Treatment of recurrent or metastatic Merkel cell carcinoma (MCC) with CISplatin and Etoposide
Treatment of Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma using Cemiplimab
Treatment of Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma using Cetuximab
